edoc

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population : 26-week data of the FACTS II survey

Vavricka, Stephan R. and Schoepfer, Alain M. and Bansky, Georg and Binek, Janek and Felley, Christian and Geyer, Martin and Manz, Michael and Rogler, Gerhard and de Saussure, Philippe and Sauter, Bernhard and Scharl, Michael and Seibold, Frank and Straumann, Alex and Michetti, Pierre and Swiss IBDnet, . (2011) Efficacy and safety of certolizumab pegol in an unselected crohn's disease population : 26-week data of the FACTS II survey. Inflammatory bowel diseases, Vol. 17, no. 7. pp. 1530-1539.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6003454

Downloads: Statistics Overview

Abstract

Certolizumab pegol (Cimzia, CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as the first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based patients.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Gastroenterologie
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Gastroenterologie
UniBasel Contributors:Straumann, Alex
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Wiley
ISSN:1078-0998
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:27 Feb 2014 15:46
Deposited On:27 Feb 2014 15:46

Repository Staff Only: item control page